ストックスクリーナーアプリを入手
0.68
2.88%
-0.0202
前日終値:
$0.7002
開ける：
$0.71
24時間の取引高:
2.48M
Relative Volume:
0.55
時価総額：
$197.84M
収益：
-
当期純損益:
$-63.08M
株価収益率:
-2.5185
EPS:
-0.27
ネットキャッシュフロー:
$-72.53M
1週間 パフォーマンス:
-5.28%
1か月 パフォーマンス:
-9.30%
6か月 パフォーマンス:
-47.29%
1年 パフォーマンス:
-35.85%
1日の値動き範囲:
$0.68
$0.71
1週間の範囲:
$0.6717
$0.7599
52週間の値動き範囲:
$0.6404
$2.105
Ocugen Inc Stock (OCGN) Company Profile
OCGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.68 | 197.84M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-15 | 開始されました | Maxim Group | Buy |
| 2023-03-01 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 開始されました | Mizuho | Buy |
| 2022-06-15 | 再開されました | ROTH Capital | Buy |
| 2022-06-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 開始されました | Noble Capital Markets | Outperform |
| 2021-06-11 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2021-05-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
すべてを表示
Ocugen Inc (OCGN) 最新ニュース
Ocugen to Announce Q4 and Full-Year 2024 Results with Live Webcast on March 5, 2025 - MyChesCo
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Ocugen to Host Conference Call on Wednesday, March 5, 2025 - GlobeNewswire
Ocugen, Inc. to Host Conference Call for Q4 and Full Year 2024 Financial Results on March 5, 2025 - Nasdaq
Is QuantumScape Stock a Buy Now? - The Globe and Mail
Ocugen Earnings: Can This Gene Therapy Pioneer Turn Financial Corner in 2024? - StockTitan
Ocugen, Inc. (OCGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
European Commission nods at Ocugen’s gene therapy By Investing.com - Investing.com Nigeria
Chardan Capital Reaffirms Buy Rating for Ocugen (NASDAQ:OCGN) - MarketBeat
HC Wainwright Issues Positive Forecast for Ocugen (NASDAQ:OCGN) Stock Price - MarketBeat
UPCOMING OCGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Why Ocugen (OCGN) Is Advancing Today - MSN
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen shares rise as H.C. Wainwright lifts price target to $8 - Investing.com Nigeria
Ocugen shares rise as H.C. Wainwright lifts price target to $8 By Investing.com - Investing.com South Africa
Expert Outlook: Ocugen Through The Eyes Of 4 Analysts - Benzinga
Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone Achieved! - MyChesCo
Ocugen, Inc. Announces Dosing Completion in the Phase 2 - GlobeNewswire
Ocugen Completes Dosing In Phase 2 ArMaDa Trial For OCU410 In Geographic Atrophy - Nasdaq
Ocugen announces dosing completion in Phase 2 ArMaDa clinical trial - TipRanks
Ocugen Completes Phase 2 Enrollment in OCU410 Clinical Trial for Geographic Atrophy Treatment - Nasdaq
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewswire
Revolutionary One-Time Gene Therapy Outperforms Monthly Injections in Macular Degeneration Trial - StockTitan
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
What's Going On With Ocugen Stock? - MSN
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
STATE STREET CORP Reduces Stake in Ocugen Inc by 62.93% - GuruFocus.com
Nasal COVID-19 vaccine based on WashU technology to enter U.S. clinical trials - WashU Medicine
Ocugen’s OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa Treatment - MSN
Ocugen's OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa Treatment - MyChesCo
European Commission nods at Ocugen's gene therapy - Investing.com India
Ocugen Announces Positive Opinion of European Medicines - GlobeNewswire
Ocugen gets positive EU opinion for ATMP classification for OCU400 - Seeking Alpha
Ocugen Says EMA Panel Issues Positive Opinion for Potential Eye Disease Treatment - Marketscreener.com
European Commission nods at Ocugen's gene therapy By Investing.com - Investing.com Australia
Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa - Ocugen
Revolutionary Eye Disease Gene Therapy Advances: Ocugen Secures Fast-Track Status in Europe - StockTitan
Ocugen Files Secondary Stock Shelf -January 31, 2025 at 04:44 pm EST - Marketscreener.com
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine - MSN
Ocugen, Inc. Announces Investigational New Drug Application - GlobeNewswire
Ocugen Inc (OCGN) 財務データ
収益
当期純利益
現金流量
EPS
Ocugen Inc (OCGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Castillo Kirsten | Director |
Nov 22 '24 |
Buy |
0.91 |
25,000 |
22,848 |
75,000 |
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):